secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001437749-22-004769
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin appoints Joy Yan, M.D., Ph.D. to Board of Directors
-------------------------------------------------------------

- Appointment effective March 1, 2022; Dr. Yan will serve as an independent director.
- Compensation includes $40,000 annual cash retainer and 10-year option for 6,667 shares vesting over 3 years.
- Dr. Yan brings experience from Bristol Myers Squibb, Janssen, Bayer; led development of nivolumab and ipilimumab.
- No board committee assignments at this time.
- Press release issued March 1, 2022; standard indemnification agreement executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774922004769/0001437749-22-004769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774922004769/mbrx20220224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-004769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer